Gene editing firm Emendo Biotherapeutics has raised $61m through a Series B financing round led by AnGes, a Japanese biopharmaceutical company.
The firm intends to apply CRISPR gene editing for a wide range of genetic diseases. Although CRISPR presents opportunities for gene editing, it also has limitations due to the specificity of nucleases.
Emendo intends to eliminate these limitations with a technology, known as OMNIa next-generation allele-specific gene-editing platform that uses synthetic biology to expand genome-editing.
The OMNI technology aims to treat dominant indications, such as Severe Congenital Neutropenia (SCN), which is caused by changes in the neutrophil elastase gene ELANE.
This financing round expands the firm’s strategic collaboration with AnGes and pharmaceutical firm Takeda.
Emendo Biotherapeutics president and CEO David Baram said: “This financing provides a strong foundation from which we can accelerate our proprietary OMNI gene-editing platform towards a broad clinical pipeline for addressing devastating untreatable diseases.
“We are grateful for such strong support from so many high-quality investors and strategic partners, including AnGes, OrbiMed Advisors, OrbiMed Israel Partners and Takeda Ventures who share our vision to translate this powerful science into transformative medicines.”
Last year, Emendo granted an option to Takeda to use the OMNI platform for two research and development programmes.
Under this option, Emendo received an undisclosed sum from Takeda Ventures, which was converted in the Series B financing.
Based in the US, Emendo is engaged in the development of next-generation genetic engineering techniques using synthetic biology to address diseases that cannot be treated.